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Ulcerative colitis associated with IgG4 cholangitis: Similar features
in two HLA identical siblingsq
Sergio Negrin Dastis1, Dominique Latinne2, Christine Sempoux3, Andre´ P. Geubel1,*
1Department of Gastroenterology and Hepatology, St. Luc University Hospital, Universite´ Catholique de Louvain,
10 Avenue Hippocrate, 1200 Brussels, Belgium
2Department of Immunology, St. Luc University Hospital, Universite´ Catholique de Louvain, Brussels, Belgium
3Department of Pathology, St. Luc University Hospital, Universite´ Catholique de Louvain, Brussels, BelgiumBackground: IgG4-associated cholangitis (IAC) can mimic primary sclerosing cholangitis although, in contrast to the
latter, it is highly responsive to steroid therapy. IAC is known to be associated with autoimmune pancreatitis and has also
been shown to be part of a more complex autoimmune IgG4 syndrome. However, an association with inﬂammatory bowel
disease (IBD), a condition in which its identiﬁcation may have therapeutic and prognostic importance, has not yet been
described.
Case reports:We report the cases of two HLA identical siblings both DRB*1501 positive exhibiting features of IAC
together with ulcerative colitis. Subsequent high resolution HLA typing performed by sequence-based-typing showed sim-
ilar alleles in both siblings: A*0301 A*3201 B*07 (0702/62) B*1401 C*0702 C*0802 DRB1*1501. There is indirect evi-
dence that this hitherto undescribed association, likely to be strongly linked to a genetic background, might account for a
proportion of the cases of cholangitis associated with IBD.
Conclusion:Appropriate investigation for IBD-associated cholangitis is mandatory to identify IAC, the recognition of
which has particular therapeutic and prognostic implications.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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IAC is known to be often associated with autoim-
mune pancreatitis (AP), although it can occasionally
be a single facet of a more complex autoimmune sys-
temic IgG4 syndrome [1,2]. It is likely that this autoim-
mune entity has been under-recognized due to few
distinguishable features from the more common picture0168-8278/$36.00  2009 European Association for the Study of the Liver.
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there are reports of patients having both PSC and AP,
a context in which the disease has been shown to be
responsive to corticotherapy, an uncommon observation
in PSC. On the other hand, increased IgG4 serum levels
have been found in 9% of unselected patients with PSC
[3], the signiﬁcance of which remains uncertain because
of the retrospective documentation of the association.
Whether this biochemical feature may be used to iden-
tify a subtype of cholangitis related to diﬀerent patho-
physiological mechanisms remains to be determined.
It is now recognized that IAC is a manifestation of a
wider autoimmune syndrome with increased IgG4 com-
monly known as IgG4 related systemic disease (ISD)
and typically responsive to steroids. Pancreatitis is the
most frequent manifestation, but other associations
have been described, involving other organs such asPublished by Elsevier B.V. All rights reserved.
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nodes [4–6]. An algorithm for the diagnosis and man-
agement of this syndrome has been constructed in the
light of occasional lack of elevated IgG4 [1].
It is widely accepted that approximately 5% of UC
patients exhibit associated PSC, a proportion which var-
ies from one study to another [7–9]. By contrast, the
majority of patients with PSC have underlying IBD
(from 23% to 72%) [10,11]. The wide variation in preva-
lence is probably related to the absence of universal
endoscopic examination and also, to variable geograph-
ical distribution. The association has important thera-
peutic and prognostic implications especially in the
context of liver transplantation, The mechanisms
involved in the pathogenesis of this common association
often characterized by serological ANCA positivity,
found in up to 80% of cases [12] remains largely
unknown.
So far, and to the best of our knowledge, no associa-
tion has been reported between IAC and deﬁnite HLA
haplotypes or between IgG4-related cholangitis and
UC. In this paper we report two cases of HLA-identical
siblings both with UC and IgG4-related cholangitis
highly responsive to low-dose steroids. This leads us to
postulate that in the spectrum of immune cholangiopa-
thy associated with inﬂammatory bowel diseases, the
identiﬁcation of such an entity has important implica-
tions for therapy and prognosis.2. Case reports
2.1. Case 1
A 17-year-old male was seen by a gastroenterologist
of another center in May 2007 because of diarrhea. A
biochemical work-up performed at the end of a short
course of ciproﬂoxacin (500 mg per day for 7 days)
showed biochemical cholestasis. Serology was negative
for hepatitis viruses, cytomegalovirus (CMV) and
Epstein–Barr virus (EBV), but high levels of anti-actine
and antinuclear antibodies were reported and a liver
biopsy was performed. Histological examination
showed features suggestive of mild chronic hepatitis
with bile duct injury. At colonoscopy, the picture was
that of a diﬀuse form of ulcerative colitis, a diagnosis
conﬁrmed by the histological examination of mucosal
biopsies. Magnetic resonance imaging (MRI) of the liver
and biliary tree showed diﬀuse irregularities of the intra-
hepatic biliary tract. Corticotherapy (methylpredniso-
lone, 32 mg per day at decreasing doses during four
months) combined with azathioprine was initiated, aza-
thioprine being rapidly withdrawn due to the occurrence
of an episode of acute pancreatitis. This was followed by
a rapid improvement of both clinical symptoms and bio-
logical tests such as liver function tests and hyper-gam-maglobulinemia. At the time of initial work-up no
serum IgG4 levels had been obtained. Therapy with ste-
roids (tapered doses) was given until November 2007
when methylprednisolone was shifted to budesonide.
The patient was then referred to our center for a second
opinion. Upon arrival, he was asymptomatic and was
kept on budesonide 6 mg per day. The liver biopsy
obtained previously was reviewed by one of the authors
(CS) who emphasized the presence of features of inter-
lobular cholangitis superimposed on those suggestive
of mild chronic hepatitis with a dense lymphocytic inﬁl-
trate of the portal triads (Fig. 1A). Immunostaining of
liver biopsy for IgG4 plasmocytic cells was positive in
a few cells. Serum IgG4 levels were normal with no
hypergammaglobulinemia, probably due to the high
doses of corticosteroids given during the previous four
months. HLA testing showed a class II DRB1*15.
Repeat MRI performed six months after the ﬁrst exam-
ination showed a complete disappearance of biliary tract
abnormalities. Moreover, there was a spectacular
improvement in the liver function tests, which had
almost returned to normal by July 2008.
2.2. Case 2
The sister of the patient was also referred to our cen-
ter on March 2007 due to liver function test abnormal-
ities and diarrhea. In October 2006, she had been
treated for urinary tract infection manifested by urinary
symptoms and fever. She was ﬁrst prescribed amoxycil-
lin-clavulanate (500 mg, 3 times per day). However,
because of the persistence of fever she was hospitalized
and treated by ciproﬂoxacin and amikacin. Biochemical
work-up performed at the time of hospitalization
showed increased ALT at 225 IU/l, and biochemical
cholestasis (alkaline phosphatase: 848 UI/l, N < 94;
gamma-GT: 880 IU/l, N < 40). Total serum bilirubin
level was 2.9 mg/dl. Hepatitis, EBV and CMV serology
was negative. There was a hypergammaglobulinemia
with increased total IgG levels (2800 mg/dl, N < 1600)
and an elevated IgG4 level at 323 mg/dl (N < 186). Anti-
nuclear antibodies were positive (1/1280, N < 1/40) as
were the ANCA (1/2560, N < 1/40) and anti-smooth
muscle antibodies (1/320, positive for actine speciﬁcity).
Tests for anti-mitochondrial antibodies and LKM1 were
negative. Abdominal tomodensitometry was normal. An
MRI of the liver was performed which was interpreted
as showing irregularities of the common bile duct. A
liver biopsy was then performed which showed a pre-
served architecture with enlarged portal tracts inﬁltrated
by lymphocytes, polynuclear neutrophils, eosinophils
and plasmocytes. Inﬂammation was often located
around interlobular ducts with pictures of bile duct
destruction and concentric periductular ﬁbrosis
(Fig. 1B and C). There was cholangiolar proliferation
but no interface hepatitis.
Fig. 1. (A) Part of an enlarged portal tract showing a dense lymphocytic inﬁltration and an interlobular bile duct also inﬁltrated with inﬂammatory cells
(hematoxylin-eosin, 40 original magniﬁcation). (B) Picture of an enlarged portal tract inﬁltrated with inﬂammatory cells (lymphocytes, polynuclear
neutrophils, eosinophils and plasmocytes) containing a severely damaged bile duct with concentric periductular ﬁbrosis (Masson’s trichrome, 10 original
magniﬁcation). (C) Higher magniﬁcation showing cholangiolitis, cholangiolar proliferation and a dense plasmocytic inﬁltration (hematoxylin-eosin, 40
original magniﬁcation). (D) IgG4 immunostaining of a portal space showing an inﬁltration with numerous IgG4 positive plasmocytic cells (arrows:
immunoperoxydase, 40 original magniﬁcation).
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was initiated in mid-November and doses were rapidly
tapered down. Liver function tests showed a slow
improvement. However, in February 2007 the patient’s
tests worsened repeatedly. At that time, the patient com-
plained of diarrhea and fever.
Due to these new clinical features and relapsing liver
tests abnormalities, the patient was referred to our cen-
ter. At clinical examination, the patient looked chroni-cally ill with pallor and acne. Colonoscopy showed a
picture of moderately active ulcerative colitis extending
to the entire colonic mucosa. Biopsies taken during this
examination showed an inﬂamed mucosa inﬁltrated by
polynuclear neutrophils and plasmocytes together with
microabcesses, a picture compatible with ulcerative coli-
tis. Repeated MRI showed diﬀuse irregularities of the
biliary tract. The recent liver biopsy was reviewed and
an immunostaining for IgG4 was obtained which
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trating portal tracts (Fig. 1D).
Treatment with ursodeoxycholic acid (750 mg per
day) and mesalazin was ﬁrst initiated. Due to only min-
imal improvement, budesonide (3 mg, 3 times per day)
was added, then tapered down after three months at
3 mg, 2 times per day. One year after the initiation of
treatment with budesonide the clinical condition of this
patient dramatically improved, with a weight increase of
5 kg. Liver biochemistry showed a regressive isolated
increase in cGT. IgG4 blood determination was reduced
to 269 mg/dl and HLA determination showed, as in her
brother, a class II DRB1*15. Subsequent high resolution
HLA typing performed by sequence-based-typing
showed in both siblings similar alleles: A*0301 A*3201
B*07 (0702/62) B*1401 Cw*0702 Cw*0802 DRB1*1501.
After a further six months follow-up, both patients
were asymptomatic. The brother had normal hepatic
and pancreatic tests as well as normal IgG4 levels.
Repeated MRI with cholangio-pancreatography per-
formed one year after the initiation of treatment showed
a complete disappearance of bile duct abnormalities in
both cases. After a three year follow-up period and
under small doses of budesonide (3–6 mg per day) both
patients remains asymptomatic with a normal liver sero-
biochemistry.3. Discussion
We report two cases of two identical siblings present-
ing with cholangitis associated with ulcerative colitis.
Both expressed IgG4 plasmocytic positivity in liver
biopsy specimens, the expression being, however, much
stronger in the sister. This was probably due to the
shorter history of the disease and its greater activity.
Serum levels of IgG4 were also higher in the sister
who had been treated with a much lower dose of ste-
roids. Both patients responded promptly to treatment
with prednisolone, the therapeutic beneﬁt being main-
tained under budesonide, ursodeoxycholic acid and
mesalazin. Clinical and biochemical response to treat-
ment was complete in both cases and MRI biliary tract
abnormalities had completely disappeared after one year
of therapy. HLA testing showed that both siblings were
class II DRB1-15 positive with high resolution typing
indicating DRB*1501, an allele more often shown in
association with PSC, but not with IgG4 cholangitis.
Cholangitis described in association with inﬂamma-
tory bowel disease includes mainly PSC, its IgG4 positive
form being less frequently observed in this context [3]. By
contrast, IgG4 cholangitis appears more often associated
with autoimmune pancreatitis, and may be a component
of a rather more diﬀuse, systemic autoimmune IgG4 dis-
ease highly responsive to steroid therapy [1].HLA studies performed in PSC have led to rather
inconsistent associations, DRB*1501 being more consis-
tently associated as in our two siblings [13,14]. Tests per-
formed in autoimmune pancreatitis in Japan have
suggested that the two critical regions for disease suscep-
tibility are limited to the HLA–DRB1*0405-
DQB1*0401 in class II and the ABCF1 proximal to
C3-2-11, telomeric of HLA-E, in the class I regions
[15–17]. The disease has also been suspected to be asso-
ciated with cytotoxic T-lymphocyte antigen four gene
polymorphism, also in Japanese patients [18]. An associ-
ation with DRB*1501 as in our siblings has not yet been
reported. Another remaining possibility is that the
DRB*1501 allele represents a predisposing factor for
bile duct involvement in patients with ISD.
From a diagnostic point of view, the diagnosis of
PSC in our two case reports was unlikely, not so much
because of atypical serological features as more impor-
tantly, based on the early and sustained disappearance
of clinical, biochemical and morphological features of
bile duct involvement. As exempliﬁed in our cases, the
clinical and biological pictures occurring in IgG4-associ-
ated cholangitis may mimic those of autoimmune hepa-
titis (AIH) or those of the AIH/PSC overlap syndrome.
Considering co-existing AIH, confusion may exist and
scoring our cases for this condition would give a score
of 12 using the 1999 scoring system and a score of 6
(probable AIH) using the simpliﬁed 2008 criteria. How-
ever, segmental and/or large extra-hepatic bile duct
involvement is not known to occur in AIH, an observa-
tion which can also be done for the AIH/PSC overlap
syndrome. In addition to the absence of positive IgG4
staining on the liver biopsy, both conditions are also
far less responsive to small doses of steroids than IAC.
Search for the identiﬁcation of IgG4 cholangitis and/
or disease through increased IgG4 serum levels and/or
increased tissular IgG4 plasmocytic expression thus
appears important both for diagnostic and therapeutic
purposes. Indeed immunosuppression is eﬀective and
may lead to long-term remission, improved prognosis
and/or transplantation-free survival. Our observations
also reinforce the concept of the existence of ISD, a dis-
ease in which the existence of a genetic predisposition
remains to be determined.4. Conclusions
Our case reports document the fact that IBD-associ-
ated autoimmune cholangitis may in some cases be part
of ISD diﬀerent from PSC and highly responsive to
steroid therapy. Moreover, the occurrence of identical
features in two HLA-identical siblings reinforces argu-
ments in favor of a strong genetic predisposition.
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